FIELD: biotechnology.
SUBSTANCE: invention relates to new therapeutic proteins and can be used in medicine. The invention discloses a bispecific fusion protein in which the second binding structural domain is inserted into the hinge region of a full length immunoglobulin G (IgG). Such a fusion protein has the same expression and production advantages as the original IgG, does not affect the binding activity of the Fab region of the fusion protein, and further improves stability and provides a longer half-life.
EFFECT: invention can be used in the treatment of various malignant neoplasms.
41 cl, 6 ex, 11 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| T-CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN p53 | 2020 |
|
RU2830061C2 |
| NGF ANTAGONISTS FOR MEDICAL USE | 2020 |
|
RU2829812C2 |
| IL4 RECEPTOR ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2019 |
|
RU2837141C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| VERSION FC AND ITS PRODUCTION | 2021 |
|
RU2828852C1 |
| LONG-ACTING FUSION PROTEIN GDF15 AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2020 |
|
RU2836280C1 |
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
